Proactive MD®, national leader in value-based care, announced the recent acquisition of a state-of-the-art liquid biopsy diagnostics company. This acquisition follows a series of recent national growth initiatives around diagnostics, pathology, pharmacy, and primary care. By integrating advanced liquid biopsy technology into its primary care model, Proactive MD aims to provide its patients with earlier and more accurate lung cancer screenings, empowering them with life-saving preventive diagnostics before symptoms appear.
Read the full article: Proactive MD Acquires Leading Lung Cancer Liquid Biopsy Company //
Source: https://www.einpresswire.com/article/787451156/proactive-md-acquires-leading-lung-cancer-liquid-biopsy-company